Current frontline endocrine treatment options for women with hormone receptorpositive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer

Despite the recent advances in breast cancer early detection and awareness, a significant portion of patients present with an advanced-stage disease and more patients will progress to stage IV despite adequate treatment of their initial early-stage disease. Hormone receptor (HR)-positive, Human Epid...

Celý popis

Podrobná bibliografie

Hlavní autor:	Hikmat Abdel-Razeq
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wolters Kluwer Medknow Publications 2019-01-01
Edice:	Hematology/Oncology and Stem Cell Therapy
Témata:	breast cancer cdk4/6 inhibitors palbociclib ribociclib abemaciclib fulvestrant
On-line přístup:	https://journals.lww.com/10.1016/j.hemonc.2018.04.002
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!